Novo Nordisk's mixed drug trial results across therapies

Key developments

1. Sep 7, 2026

   Novo Nordisk halts two more ziltivekimab heart-failure trials after a data monitor found limited likelihood of success, leaving only the ARTEMIS post-MI study active.

   8 sources on this →
2. Sep 7, 2026

   Novo Nordisk's STEP Young trial shows once-weekly semaglutide plus lifestyle changes lifted 40.4% of children aged 6-11 with obesity out of the obesity category after 68 weeks.

   6 sources on this →

Coverage across the spectrum

Stories in this storyline

Health

Novo Nordisk Halts Two Ziltivekimab Heart Trials

Novo Nordisk has halted two more ziltivekimab trials in heart failure after a data monitor found limited likelihood of success, adding to the earlier ZEUS setback and leaving only the post‑myocardial infarction ARTEMIS study as the remaining program. A separate post‑MI study is continuing with results expected in early 2027, underscoring ongoing challenges for inflammation‑targeting cardiovascular therapies.

8 sources

Health

Novo says Wegovy trial moved 40% of young children out of obesity

In Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.